Posted by Michael Wonder on 26 Jul 2021
BeiGene announces approval in Canada of Brukinsa (zanubrutinib) for the treatment of patients with mantle cell lymphoma
26 July 2021 - Second approval for BTK inhibitor Brukinsa in Canada.
BeiGene today announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of mantle cell lymphoma in adult patients who have received at least one prior therapy.
